InvestorsHub Logo
Followers 55
Posts 3324
Boards Moderated 0
Alias Born 06/13/2020

Re: None

Wednesday, 02/09/2022 3:52:27 AM

Wednesday, February 09, 2022 3:52:27 AM

Post# of 2196
NEWS: WOW!!!

Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ITRM News